<DOC>
	<DOC>NCT02413593</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) plus ribavirin (RBV) in treatment-naive adults with chronic genotype 3 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Key Chronic genotype 3 HCV infection HCV treatmentnaive HCV RNA &gt; 10,000 IU/mL at screening Absence of cirrhosis or compensated cirrhosis Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Key Pregnant or nursing female or male with pregnant female partner Coinfection with HIV or hepatitis B virus (HBV) Current or prior history of clinical hepatic decompensation Chronic use of systemic immunosuppressive agents History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HCV genotype 3 (GT-3)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Ledipasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
</DOC>